Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy

Fabry Disease Clinical Trial

— FABRY  

Official title:

Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03230149
• Other study ID #: HAO16026
• Status: Completed
• Start date: March 12, 2018
• Est. completion date: December 24, 2021

Study information

• Verified date: September 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist. Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain). Aims will be to determine the prevalence of Fabry disease in patients with stroke or small fiber neuropathy, and their characteristics

Description:

FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist. Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain). 1. Considering strokes, they are the third leading cause of death in France, with more than 140,000 people presenting a stroke per year. Stroke incidence is 1-2/1000 people per year. If the mean age of stroke patient is 72 yo, 25% of them are under 55 yo. The etiology of stroke in young patients remains undetermined in up to half of the cases. Data on prevalence of FD in people with cryptogenic ischaemic stroke are limited and controversial. In addition to cryptogenic strokes, FD can lead to stroke from arterial or heart diseases (secondary to high blood pressure, renal insufficiency, cardiomyopathy, rate variability, arrhythmias, valvular insufficiency). The investigators aimed to evaluate the frequency of FD in a cohort of stroke patients in tertiary stroke centers in consecutively recruited patients under 60 yo. The investigators will include patients with so-called cryptogenic stroke but also stroke patients due to large artery atherosclerosis, cardioembolism, and small-vessel occlusion. The investigators will also study the clinical and radiological characteristic of stroke patients due to FD, and will compare these data with those from patients without FD, supported by biochemical and genetic findings. 2. Considering peripheral nervous system, Small fiber neuropathy (SFN) is a subgroup of peripheral neuropathy which is characterized by an affection of the thin myelinated A-δ and unmyelinated C-fibers. SFN patients present with sensory symptoms and pain. SFN are not a rare condition; recent study showed a minimum prevalence of 50/100.000. The most commonly etiology reported for SFN is diabetes mellitus ; Other possible etiologies include connective tissue disease, celiac disease, thyroid dysfunction, vitamin B12 deficiency, monoclonal gammopathy, HIV and hepatitis C infections, amyloidosis, toxicity due to alcohol or drugs, and hereditary neuropathies including FD, suspected to be underdiagnosed. In SFN patients,the investigators aimed to screen for FD in our tertiary national center for peripheral neuropathies, in addition to others diseases or affections, to evaluate the frequency of FD in a large cohort of SFN patients, and describe the clinical phenotype of SFN in FD patients compared to other ones.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 379
• Est. completion date: December 24, 2021
• Est. primary completion date: December 24, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• patient over 18 yo and under 60 yo
• diagnosed with a TIA / stroke (ischemic and haemorrhagic strokes) based on clinical evaluation and MRI
• diagnosed with small fibers neuropathy (SFN) with normal nerve conduction studies in conventional electrophysiology

Exclusion Criteria:

• patients over 60 yo

Related Conditions & MeSH terms

• Fabry Disease
• Small Fiber Neuropathy

Intervention

Diagnostic Test:
• Measurements of the alpha-GAL enzyme activity
Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.

Locations

Country	Name	City	State
France	CHU de Bicêtre, UNSIV (neurovascular stroke unit)	Le Kremlin Bicêtre

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Shire International GmbH

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	frequency of FD in a cohort of stroke patients	number of patients with fabry disease in the cohort of stroke patients (1000 patients)	at the end of the study (an average of 2 years)
Secondary	frequency of FD in a cohort of Small fiber neuropathy (SFN) patients	number of patients with fabry disease in the cohort of small fiber neuropathy patients (100 patients)	at the end of the study (an average of 2 years)